---
aliases: >-
  /news/diabetes-remains-fastest-growing-medtech-market-despite-some-risk-from-new-drugs-analysts
archetype: curated-content
author:
  - Athira K
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - >-
    Diabetes remains fastest-growing MedTech market despite some risk from new
    drugs: analysts
categories:
  - 'Symplur: Diabetes Education'
  - 'The Healthcare Guys: Medtech & Devices'
  - 'The Healthcare Guys: Drugs'
categorySlug:
  - 'symplur: diabetes education'
  - 'the healthcare guys: medtech & devices'
  - 'the healthcare guys: drugs'
categoryUrl:
  - topic/symplur-diabetes-education
  - topic/the-healthcare-guys-medtech-devices
  - topic/the-healthcare-guys-drugs
categoryLabel:
  - Diabetes Education
  - Medtech & Devices
  - Drugs
contentCategories: netspective-medigy-news-curated-content
institution: null
offering: null
layOut: single
date: '2023-07-07'
description: >-
  Eli Lilly and Novo Nordisk shared information about a new class of diabetes
  and weight-loss medications at the ADA meeting. Companies have predicted that
  the treatments will bring in billions of dolla
favIconImage: null
featuredImage:
  alt: >-
    Diabetes remains fastest-growing MedTech market despite some risk from new
    drugs: analysts
  format: JPEG
  href: def911dc-3d34-5c04-a7e7-cbbd7e383660-featuredImage.jpeg
  size:
    - 435
    - 770
  valid: true
  workPackage: 19076
  wpAttachment:
    fileName: Curated_Featured_Image.jpg
    link: /api/v3/attachments/35944/content
featuredPdf: null
htmlMetaData:
  author: null
  description: null
  generator: null
  viewport: null
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: MedTech industry news
  ogimage: null
  ogsite_name: null
  ogtitle: >-
    Diabetes remains fastest-growing MedTech market despite some risk from new
    drugs: analysts
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: null
id: 19076
identifier: News
lastMod: '2023-07-07T09:00:03.916754Z'
link:
  brand: medtechdive.com
  href: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
  original: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
href: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
original: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
mastHead: NEWS
mdName: def911dc-3d34-5c04-a7e7-cbbd7e383660.md
openGraphMetaData:
  ogdescription: MedTech industry news
  ogtitle: >-
    Diabetes remains fastest-growing MedTech market despite some risk from new
    drugs: analysts
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
  medigyTopics:
    - 'Symplur: Diabetes Education'
    - 'The Healthcare Guys: Medtech & Devices'
    - 'The Healthcare Guys: Drugs'
  sourceUrl: 'https://www.medtechdive.com/news/diabetes-growth-medtech-ozempic/654388/'
openProjectWorkPackageType: Curated Content
searchCategory: News
slug: >-
  medtechdive-diabetes-remains-fastest-growing-medtech-market-despite-some-risk-from-new-drugs-analysts
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: >-
  Diabetes remains fastest-growing MedTech market despite some risk from new
  drugs: analysts
via: ' '
insights_description: ''
insights_name: ''
viaLink: null
relatedOfferings:
  - label: Care4Sugar - Diabetes Reversal Program
    permalink: /offering/care4sugar---diabetes-reversal-program
    categories:
      - 'Symplur: Diabetes Education'
      - 'Medigy: Digital Diabetes'
      - 'Medigy: Personalized Medicine'
    offeringId: 18337
  - label: Shalya's Aquaflow-Suction Irrigation Pump
    permalink: /offering/shalyas-aquaflow-suction-irrigation-pump
    categories:
      - 'Symplur: Medical Devices'
      - 'The Healthcare Guys: Medtech & Devices'
      - 'Medical Subject Headings (MeSH): Equipment and Supplies'
    offeringId: 14049
  - label: Shalya's Endolux-LED Light Source
    permalink: /offering/shalyas-endolux-led-light-source
    categories:
      - 'Symplur: Medical Devices'
      - 'The Healthcare Guys: Medtech & Devices'
      - 'Medical Subject Headings (MeSH): Equipment and Supplies'
    offeringId: 14048
  - label: Shalya's Endojet-CO2 insufflator
    permalink: /offering/shalyas-endojet-co2-insufflator
    categories:
      - 'Symplur: Medical Devices'
      - 'The Healthcare Guys: Medtech & Devices'
      - 'Medical Subject Headings (MeSH): Equipment and Supplies'
    offeringId: 14045
  - label: Diabetes Software from Glooko
    permalink: /offering/diabetes-software-from-glooko
    categories:
      - 'Symplur: Diabetes Education'
      - 'Healthcare IT News: Disease Management'
    offeringId: 5763
twitterMetaData:
  twittercard: null
  twitterdescription: MedTech industry news
  twittertitle: >-
    Diabetes remains fastest-growing MedTech market despite some risk from new
    drugs: analysts
  twitterimage: null
  twitterurl: null
---
<p>Eli Lilly and Novo Nordisk shared information about a new class of diabetes and weight-loss medications at the ADA meeting. Companies have predicted that the treatments will bring in billions of dollars annually in the coming years due to links between the class of compounds, which includes Ozempic, and weight reductions of 15% and more. By altering the use of insulin, new diabetic medications could put "short-lived pressures" on MedTech firms, claim analysts at Mizuho. The question of whether demand for insulin, insulin delivery devices, and blood glucose management solutions will continue to climb in the coming years has been raised by the introduction of Following the annual &nbsp;conferee&nbsp;new&nbsp;medications&nbsp;that&nbsp;regulate blood&nbsp;sugar&nbsp;and&nbsp;promote&nbsp;weight&nbsp;loss.</p>